Solid Biosciences (SLDB) Capital Expenditures (2017 - 2024)
Historic Capital Expenditures for Solid Biosciences (SLDB) over the last 8 years, with Q4 2024 value amounting to $204000.0.
- Solid Biosciences' Capital Expenditures rose 12666.67% to $204000.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $654000.0, marking a year-over-year decrease of 5683.17%. This contributed to the annual value of $654000.0 for FY2024, which is 5683.17% down from last year.
- Solid Biosciences' Capital Expenditures amounted to $204000.0 in Q4 2024, which was up 12666.67% from $15000.0 recorded in Q3 2024.
- In the past 5 years, Solid Biosciences' Capital Expenditures ranged from a high of $1.1 million in Q2 2022 and a low of $15000.0 during Q3 2024
- For the 5-year period, Solid Biosciences' Capital Expenditures averaged around $368200.0, with its median value being $275000.0 (2022).
- As far as peak fluctuations go, Solid Biosciences' Capital Expenditures soared by 100000.0% in 2021, and later plummeted by 9608.36% in 2024.
- Over the past 5 years, Solid Biosciences' Capital Expenditures (Quarter) stood at $60000.0 in 2020, then skyrocketed by 1000.0% to $660000.0 in 2021, then rose by 29.7% to $856000.0 in 2022, then tumbled by 89.49% to $90000.0 in 2023, then surged by 126.67% to $204000.0 in 2024.
- Its last three reported values are $204000.0 in Q4 2024, $15000.0 for Q3 2024, and $286000.0 during Q2 2024.